SCHEMBL24488778

SCHEMBL24488778

CNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 12/20 0.58
HDAC1 Q13547 5/20 0.54
HDAC3 O15379 3/20 0.54
HDAC2 Q92769 3/20 0.54
HDAC8 Q9BY41 3/20 0.54
HDAC7 Q8WUI4 2/20 0.54
HDAC4 P56524 1/20 0.54
HDAC10 Q969S8 1/20 0.54
HDAC5 Q9UQL6 1/20 0.54
NCOR2 Q9Y618 1/20 0.54
BAZ2B Q9UIF8 1/20 0.53
GRM5 P41594 1/20 0.48
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PLK1 P53350 1/20 0.41
HPGDS O60760 1/20 0.40
PSMD14 O00487 1/20 0.40
STAMBP O95630 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19505428 0.87 HDAC6 (0.60) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL6879552 0.84 ALDH1A1 (0.55) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL19267854 0.84 HDAC6 (0.58) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL19267853 0.83 HDAC6 (0.54) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL18294907 0.81 HDAC6 (0.51) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL26079021 0.79 HDAC6 (0.79) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL10050271 0.79 HDAC6 (0.81) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL21943233 0.78 HDAC6 (0.51) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL24172360 0.77 HDAC6 (0.54) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL6881495 0.75 P2RY12 (0.49) HDAC6HDAC1HDAC3HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3468559-B1 METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HDAC INHIBITORS WITH BET INHIBITORS DANA FARBER CANCER INST INC (US) 2023-11-22 EP disclosed
US-20220401474-A1 HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF MEDSTAR HEALTH 2022-12-22 US disclosed
EP-3060217-B1 TREATMENT OF POLYCYSTIC DISEASES WITH AN HDAC6 INHIBITOR MAYO FOUND MEDICAL EDUCATION & RES (US) 2022-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220401474-A1 HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF HDAC6, HDAC1, HDAC3 HDAC6 1/4885HDAC1 2/4885HDAC3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.